Disease Areas:
Idiopathic pulmonary fibrosis, CoughDevice Types:
VitaloJAKThis Phase 2, randomized, double-blind, crossover, proof-of-concept trial examined the effects of an extended-release formulation of nalbuphine in 26 adult patients with IPF-related chronic cough. The primary endpoint was the percent change from baseline in hourly daytime cough frequency, which was objectively measured using the Vitalograph VitaloJAK digital cough monitor.
